Dural Puncture Epidural VS Standard Epidural on Physician Top-ups During Labour Analgesia
Launched by CIUSSS DE L'EST DE L'ÎLE DE MONTRÉAL · Jan 25, 2021
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different methods of pain relief for women during labor: the dural puncture epidural and the standard epidural. The goal is to see which method requires fewer extra doses from doctors to manage pain during the first stage of labor. This study is currently recruiting healthy pregnant women aged 18 and older who are planning to have an epidural for pain relief during labor.
To be eligible, women must be at term (between 37 to 42 weeks of pregnancy), have a single baby in the correct position for birth, and have a cervix that is not more than 5 centimeters dilated. They should also speak French and have a body mass index (BMI) of 40 or less. Women with certain pregnancy complications or health issues, as well as those with allergies to medications used in the study, will not be eligible. Participants in the trial can expect to receive either of the two pain relief techniques and will help researchers understand which one works better in reducing the need for additional medical help during labor.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Healthy pregnant women (ASA 1 and 2) requesting epidural analgesia during labour.
- • 2. Primiparous and multiparous parturients at term gestation (37 to 42 weeks).
- • 3. Women 18 years old and older.
- • 4. Administration of epidural analgesia between 7am and 4pm on weekdays.
- • 5. Singleton and vertex presentation foetus.
- • 6. Cervical dilatation ≤ 5 cm.
- • 7. BMI ≤ 40.
- • 8. French speaking
- Exclusion Criteria:
- • 1. Pregnancy diseases such as gestational hypertension, preeclampsia and gestational diabetes.
- • 2. Contraindications to neuraxial analgesia: thrombocytopenia \< 70 x 109/L, spinal cord anomalies, anticoagulation therapy, etc.
- • 3. Known important fetal anomalies.
- • 4. Allergy to any of the medications used in the study.
- • 5. Suspected chorioamnionitis with spontaneous premature rupture of membranes (PROM).
- • 6. Difficulty understanding and speaking French.
About Ciusss De L'est De L'île De Montréal
Ciusss de l'Est de l'Île de Montréal is a leading healthcare organization dedicated to enhancing the health and well-being of the communities it serves. As a prominent clinical trial sponsor, Ciusss de l'Est conducts innovative research aimed at advancing medical knowledge and improving patient outcomes. With a focus on collaboration and ethical standards, the organization fosters a multidisciplinary approach to clinical research, ensuring rigorous methodologies and comprehensive patient care. Through its commitment to scientific excellence and community health, Ciusss de l'Est plays a vital role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials